Literature DB >> 3591271

Effects of baricity and mass of bupivacaine solutions in spinal anesthesia.

A Siaens, M De Rood.   

Abstract

We studied the effects of three different solutions of bupivacaine, injected intrathecally. Each solution had a volume of 3 ml and differed from the others by its mass or its baricity. Sixty-five patients, divided into three groups, remained in the sitting position for one minute after injection of the tested solutions. Group 1 received 10 mg of hyperbaric bupivacaine, group 2 received 10 mg of isobaric bupivacaine and group 3 received 15 mg of isobaric bupivacaine. Groups 1 and 2 showed no statistical difference in maximal extension of analgesia (T 11 and T 10), nor in mean duration of analgesia (155 and 159 min.). The motor block was similar in both groups (score less than 2 using the Bromage scale 0-3). Group 3 had a higher level of maximal cephalad extension and a longer mean duration of analgesia (186 min.). The motor block was more pronounced after 30 min. (85% score 3) compared to the two other groups. The decrease in mean arterial pressure was moderate and similar in the three groups. In view of the results of this study, we suggest the use of 3 ml of 0.5% isobaric bupivacaine injected intrathecally.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3591271

Source DB:  PubMed          Journal:  Acta Anaesthesiol Belg        ISSN: 0001-5164


  3 in total

1.  No sensory block with spinal bupivacaine a case report.

Authors:  A Stav; L Ovadia; L Keslin; N Weksler
Journal:  J Anesth       Date:  1990-07       Impact factor: 2.078

2.  Comparison of two different doses of intrathecal levobupivacaine for transurethral endoscopic surgery.

Authors:  Secil Dizman; Gurkan Turker; Alp Gurbet; Elif Basagan Mogol; Suat Turkcan; Ziyaatin Karakuzu
Journal:  Eurasian J Med       Date:  2011-08

3.  Intrathecal hyperbaric versus isobaric bupivacaine for adult non-caesarean-section surgery: systematic review protocol.

Authors:  Vishal Uppal; Harsha Shanthanna; Christopher Prabhakar; Dolores M McKeen
Journal:  BMJ Open       Date:  2016-05-18       Impact factor: 2.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.